Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
R-268712
Cat. No.:
OB0225LY-0214
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
R-268712 is a specific activin receptor-like kinase 5 (ALK5) inhibitor and is specifically developed to regulate intracellular metabolic processes.
Synonym:
879487-87-3; R268712; 2-[4-[2-Fluoro-5-[3-(6-methylpyridine-2-yl)-1H-pyrazol-4-yl] phenyl] pyrazol-1-yl]ethanol; 2-(4-(2-Fluoro-5-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)phenyl)-1H-pyrazol-1-yl)ethan-1-ol; 2-[4-[2-Fluoro-5-[5-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]phenyl]pyrazol-1-yl]ethanol
CAS No.:
879487-87-3
Compound CID:
11703284
Formula:
C20H18FN5O
Formula Weight:
363.39
Specification
Relative Density:
1.34 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
R-268712 can be used for metabolic disease research.
Library Information
Targets:
TGF-β receptor family
Receptors:
ALK5
Pathways:
TGF-beta/Smad signaling; Angiogenesis; Stem cells
Plate Number:
AOCL-3
Plate Location:
f8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
110 mg/mL; 302.7 mM
